APP and Alzheimer disease: The genetic reduction of apoA-IV in 5×FAD APP/PS1 transgenic AD mice (5×FAD APP/PS1; apo-IV−/−) augments the Aβ burden and aggravates neuronal loss in the brain compared to 5×FAD APP/PS1 transgenic mice with apoA-IV [196].